Skip to main content

Table 1 Baseline characteristics of the study population

From: Pulmonary rehabilitation after exacerbation of bronchiectasis: a pilot randomized controlled trial

Characteristics Patients enrolled at baseline Patients randomized Pulmonary rehabilitation (PR) Standard care (SC) p-value (comparing PR vs SC)
N 48 27 9 18  
Age (years) 68 (63–72) 68 (63–72) 68 (63–71) 68 (63–73) 0.8
Sex (% female) 31 (64.6%) 20 (74.1%) 5 (55.6%) 15 (83.3%) 0.2
Comorbidities
 Angina 4 (8.3%) 1 (3.7%) 0 (0%) 1 (8.3%) 1.0
 Myocardial infarction 3 (6.3%) 0 (0%) 0 (0%) 0 (0%) 1.0
 Osteoporosis 5 (10.4%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
 Anxiety 7 (14.6%) 5 (18.5%) 2 (22.2%) 3 (16.7%) 1.0
 Diabetes 5 (10.4%) 3 (11.1%) 1 (11.1%) 2 (11.1%) 1.0
 Hypertension 12 (25.0%) 9 (33.3%) 2 (22.2%) 7 (38.9%) 0.7
Smoking status
 Never 31 (64.6%) 18 (66.7%) 7 (77.8%) 11 (61.1%) 0.6
 Ex 14 (29.2%) 8 (29.6%) 1 (11.1%) 7 (38.9%)  
 Current 3 (6.3%) 1 (3.7%) 1 (11.1%) 0 (0%)  
Medications
 Inhaled corticosteroids 22 (45.8%) 16 (59.3%) 6 (66.7%) 10 (55.6%) 0.7
 Macrolide 28 (58.3%) 17 (63.0%) 6 (66.7%) 11 (61.1%) 1.0
 Other long term antibiotic 2 (4.2%) 1 (3.7%) 0 (0%) 1 (5.6%) 1.0
 Inhaled antibiotic 1 (2.1%) 1 (3.7%) 0 (0%) 1 (5.6%) 1.0
Disease severity
Exacerbations per year
 1 14 (29.2%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
 2 8 (16.7%) 8 (29.6%) 4 (44.4%) 4 (22.2%)  
 3 or more 26 (54.2%) 15 (55.6%) 3 (33.3%) 12 (66.7%)  
 Body mass index 27.3 (24.1–30.8) 27.7 (24.5–31.5) 30.7 (25.3–33.3) 26.8 (23.1–30.5) 0.3
 FEV1 1.79 (1.19–2.11) 1.78 (1.19–2.06) 1.98 (1.10–2.50) 1.71 (1.25–2.05) 0.5
 FEV1% predicted 81.5 (53.3–102) 81 (52–96) 76.0 (46.5–109) 83 (55.8–90.8) 0.4
 FVC 2.76 (2.25–3.74) 2.69 (2.24–3.34) 2.92 (2.17–3.86) 2.67 (2.18–3.22) 0.5
 6-min walk distance (m) 432 (334–497) 434 (348–500) 414 (280–494) 448 (400–507) 0.6
Bronchiectasis severity index
 Mild 9 (18.8%) 6 (22.2%) 2 (22.2%) 4 (22.2%) 0.9
 Moderate 20 (41.7%) 10 (37.0%) 4 (44.4%) 6 (33.3%)  
 Severe 19 (39.6%) 11 (40.7%) 3 (33.3%) 8 (44.4%)  
Microbiology at baseline
Haemophilus influenzae 17 (35.4%) 9 (33.3%) 3 (33.3%) 6 (33.3%) 1.0
Moraxella catarrhalis 8 (16.7%) 5 (18.5%) 1 (11.1%) 4 (22.2%) 0.6
 Enterobacteriaceae 7 (14.6%) 5 (18.5%) 2 (22.2%) 3 (16.7%) 1.0
Pseudomonas aeruginosa 6 (12.5%) 4 (14.8%) 2 (22.2%) 2 (11.1%) 0.6
 Others 10 (20.8%) 4 (14.8%) 1 (11.1%) 3 (16.7%) 1.0